Department of Dermatology and Allergology, Ludwig-Maximilian University, Munich, Germany.
Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
J Eur Acad Dermatol Venereol. 2018 Apr;32 Suppl 1:1-15. doi: 10.1111/jdv.14846.
Atopic dermatitis (AD) is a common, highly pruritic, chronic inflammatory skin disease. Dysfunction of the epidermal barrier is witnessed by an increased transepidermal water loss in lesional and non-lesional AD skin. The inflammation in lesional AD skin is well characterized. Non-lesional skin of AD patients shows histological signs of a subclinical inflammation and a pro-inflammatory cytokine milieu. This microinflammation is present even in seemingly healed skin and must be taken into account regarding treatment of AD. Emollients provide a safe and effective method of skin barrier improvement, because they provide the skin with a source of exogenous lipids, thus improving its barrier function. The use of emollients is recommended for all AD patients irrespective of overall disease severity. Patients with moderate to severe AD should combine the emollients with a proactive therapy regimen of topical calcineurin inhibitors or topical corticosteroids. Skin areas affected by active eczema in flare should receive daily anti-inflammatory therapy first before introducing emollients, to induce rapid relief of skin lesions and pruritus. The microinflammation persisting in seemingly healed AD lesions should be addressed by a proactive treatment approach, consisting of minimal anti-inflammatory therapy and liberal, daily use of emollients. An emollient containing an extract of Rhealba oat plantlet has shown anti-inflammatory and barrier repairing properties, and was clinically tested in studies targeting the microinflammation in AD. All emollients based on Rhealba oat plantlet extract are free of oat protein, as the Rhealba extract is derived from the aerial parts of the oat plantlet and is unrelated to oatmeal proteins. The Rhealba oat plantlet extract is produced in a specific process, allowing the extraction of high levels of active principles such as flavonoids and saponins, whilst being virtually free of oat proteins to minimize the risk for allergic reactions.
特应性皮炎（AD）是一种常见的、高度瘙痒的慢性炎症性皮肤病。在病变和非病变的 AD 皮肤中，经表皮水分流失增加证明表皮屏障功能障碍。病变 AD 皮肤的炎症特征明显。AD 患者的非病变皮肤表现出亚临床炎症和促炎细胞因子环境的组织学迹象。这种微炎症甚至存在于看似愈合的皮肤中，在治疗 AD 时必须考虑到这一点。保湿剂提供了一种安全有效的改善皮肤屏障的方法，因为它们为皮肤提供了外源性脂质的来源，从而改善其屏障功能。建议所有 AD 患者使用保湿剂，无论其整体疾病严重程度如何。中重度 AD 患者应将保湿剂与外用钙调神经磷酸酶抑制剂或外用皮质类固醇的主动治疗方案相结合。在引入保湿剂之前，应首先对处于急性发作期的湿疹活跃皮肤区域进行每日抗炎治疗，以迅速缓解皮肤病变和瘙痒。在看似愈合的 AD 病变中持续存在的微炎症应通过主动治疗方法来解决，包括最小化抗炎治疗和自由、每日使用保湿剂。含有 Rhealba 燕麦幼苗提取物的保湿剂已显示出抗炎和屏障修复特性，并在针对 AD 微炎症的研究中进行了临床测试。所有基于 Rhealba 燕麦幼苗提取物的保湿剂均不含燕麦蛋白，因为 Rhealba 提取物来自燕麦幼苗的地上部分，与燕麦蛋白粉无关。Rhaalba 燕麦幼苗提取物是在特定工艺中生产的，允许提取高水平的活性成分，如类黄酮和皂苷，同时几乎不含燕麦蛋白，以最大程度降低过敏反应的风险。
